GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 22, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on August 22, 2025, that it has purchased a number of its own ordinary shares. The transactions were carried out through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not indicate any new material risks.
Key Players & Entities
- GSK plc (company) — The company making the share purchases.
- Merrill Lynch International (company) — The corporate stockbroker acting on behalf of GSK.
- August 2025 (date) — The reporting period for the transactions.
- August 22, 2025 (date) — The date of the announcement.
FAQ
What is the total number of GSK ordinary shares purchased?
The filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What was the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount spent on the share repurchases.
Through which broker did GSK execute these share purchases?
GSK acted through its corporate stockbroker, Merrill Lynch International.
What is the par value of GSK's ordinary shares?
The ordinary shares are stated to be of 31¼ pence each.
Is this a routine filing for GSK?
Yes, this is a Form 6-K, which is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, often used for reporting material events or transactions.
Filing Stats: 2,921 words · 12 min read · ~10 pages · Grade level 4.3 · Accepted 2025-08-22 09:29:40
Filing Documents
- a3348w.htm (6-K) — 8100KB
- 0001654954-25-009943.txt ( ) — 8101KB
From the Filing
IN OWN SHARES a3348w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .         Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase:   21 August 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   238,918   Lowest price paid per share (GBp):   1,473.00p   Highest price paid per share (GBp):   1,492.00p   Volume-weighted average price paid per share (GBp):   1,485.14p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 25,029,256 ordinary shares.   Following the above purchase, the Company will hold 243,163,639 ordinary shares in treasury and have 4,072,228,095 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,072,228,095. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.97 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:      GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     21 August 2025 Investment firm:        Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   238,918   1,492.00p   1,473.00p   1,485.14p   CBOE ( CHIX)   0   -   -   -   CBOE ( BATE)   0   -   -   -       Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   3   1,477.50    XLON   21-Aug-2025   08:00:05   0XL0611000000000ASO31G   3   1,477.50    XLON   21-Aug-2025   08:00:05   0XL0640000000000ASO2TS   4   1,477.50    XLON   21-Aug-2025   08:00:05   0XL06A0000000000ASO30P   8   1,477.50    XLON   21-Aug-2025   08:00:05   0XL0611000000000ASO31F   9   1,477.50    XLON   21-Aug-2025   08:00:05   0XL0640000000000ASO2TP   11   1,477.50    XLON   21-Aug-2025   08:00:05   0XL0611000000000ASO31E   11   1,477.50    XLON   21-Aug-2025   08:00:05   0XL0640000000000ASO2TT   11   1,477.50    XLON   21-Aug-2025   08:00:05   0XL0670000000